There’s No Getting Around Royalty Pharma plc (NASDAQ: RPRX) Success

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

RPRX belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $29.26 and fluctuated between $29.61 as its day high and $28.60 as its day low. The current market capitalization of Royalty Pharma plc is $13.14B. A total of 3.61 million shares were traded on the day, compared to an average of 1.01 shares.

In the most recent transaction, RIGGS RORY B sold 35,702 shares of RPRX for 27.55 per share on Jan 04. After the transaction, the Director now owns 20,099 company shares. In a previous transaction on Jan 03, RIGGS RORY B sold 199,098 shares at 27.79 per share. RPRX shares that Director owns now total 55,801.

Among the insiders who sold shares, RIGGS RORY B disposed of 235,200 shares on Jan 02 at a per-share price of $28.52. This resulted in the Director holding 254,899 shares of RPRX after the transaction. In another insider transaction, Avara Management Ltd sold 65,803 shares at $28.04 per share on Dec 29. Company shares held by the 10% Owner now total 2,477,520.

Dividend

Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. Royalty Pharma plc pays an annual dividend of $0.89 (3.03%), resulting in a dividend yield of 0.80 (2.73%), and it has a price to earnings (P/E) ratio of 73.11. RPRX’s most recent ex-dividend date was 2/15/2024 when it declared a $0.21 quarterly dividend that was paid in cash on 3/15/2024. Previously, the company paid the dividend on 12/15/2023 with an ex-dividend date of 11/16/2023. The RPRX stock dividend was $0.20 per share in cash.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for RPRX in the last 3 months, the mean price target is $43.57 with high estimates of $56.00 and low estimates of $37.00. In terms of 52-week highs and lows, RPRX has a high of $38.51 and a low of $25.92.

As of this writing, RPRX has an earnings estimate of $0.99 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of $1.02 per share and a lower estimate of $0.92. The company reported an EPS of $0.84 in the last quarter, which was 3.70% higher than expectations of $0.81.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. RPRX’s latest balance sheet shows that the firm has $2.80B in Cash & Short Term Investments as of fiscal 2021. There were $7.10B in debt and $171.25M in liabilities at the time. Its Book Value Per Share was $13.77, while its Total Shareholder’s Equity was $10.25B.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RPRX is Buy with a score of 4.71.

Most Popular

Related Posts